Klotho Neurosciences Announces Pre-Clinical Success in Anti-Aging Therapy Using AAV-Delivered s-KL

NEW YORK, June 9, 2025 /PRNewswire/ –Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biogenetics company, has announced promising pre-clinical study findings suggesting that increasing Klotho gene expression could simultaneously reduce age-associated degeneration across multiple organs, thereby extending both life and health span.

The company’s focus is on developing a treatment to reduce age-associated degeneration, with a particular emphasis on neurodegenerative diseases such as ALS, Alzheimer’s, and Parkinson’s disease. The therapeutic approach involves the use of adeno-associated virus (AAV) technology.

This announcement builds upon pioneering discoveries by Professor Makoto Kuro-O in 1997, which established a direct link between Klotho concentrations in the blood and mammal lifespan. His subsequent research showed that genetic overexpression of full-length Klotho in mice extended their lifespan by 30-40%. The Klotho protein has since garnered significant attention for its influence on biological pathways related to metabolism, inflammation, and tissue repair, all of which are closely tied to the aging process.

More recently, research led by Joan Roig-Soriano and colleagues, published in Molecular Therapy in February 2025, highlighted the potential of the naturally occurring secreted form of the Klotho protein (“s-KL”). Their experiments in healthy aging mice and mice with a rapidly aging phenotype showed that s-KL, delivered via an adeno-associated virus serotype 9 (AAV9) vector, effectively increased serum s-KL concentrations, leading to a 20% increase in lifespan. The studies suggest s-KL could be a promising anti-aging therapeutic due to its broad effects on cell injury, stress, and inflammation pathways.

Dr. Joseph Sinkule, CEO of Klotho Neurosciences, stated that KLTO has secured an exclusive worldwide license for s-KL from Universitat Autònoma de Barcelona (UAB) and Institució Catalana de Recerca i Estudis Avançades (ICREA) in Spain. This license grants KLTO exclusive use of patents in the USA, Europe, and China for s-KL as a treatment for neurodegenerative and age-related disorders. Professor Makoto Kuro-O also serves as a scientific advisor to KLTO, further validating the company’s approach.